An alternative strategy could involve incorporating glucagon or glucagon receptor agonists in conjunction with insulin and GLP-1 receptor agonists, targeting the complex interplay between these hormones and potentially offering benefits for both insulin-deficient diabetes and obesity management. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.